HER-2/neu expression in prostate adenocarcinoma: A systematic review and meta-analysis

Journal of Urology

Volumn 184, Issue 3, 2010, Pages 842-850

  Neto, Ary Serpa ^a   Tobias Machado, Marcos ^a,b   Wroclawski, Marcelo Langer ^a,b   Fonseca, Fernando Luiz Affonso ^a   Teixeira, Gabriel Kushiyama ^a   Amarante, Rodrigo Dal Moro ^a   Wroclawski, Eric Roger ^a,b   Del Giglio, Auro ^a,b  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

adenocarcinoma; genes, erbB 2; mortality; neoplasm recurrence, local; prostate

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; EMBASE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; MEDLINE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; ADENOCARCINOMA; BIOSYNTHESIS; BLOOD; MALE; META ANALYSIS; METABOLISM; PROSTATE TUMOR; REVIEW;

ADENOCARCINOMA; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 77956629278     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.04.077     Document Type: Review

References (28)

1. R.R. Beerli, D. Graus-Porta, and K. Woods-Cook Neu differentiation factor activation of erbB-3 and erbB-4 is cell specific and displays a differential requirement for erbB-2 Mol Cell Biol 15 1995 6496
2. M. De Laurentiis, G. Arpino, and E. Massarelli A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer Clin Cancer Res 11 2005 4741
3. F. Lonardo, E. Di Marco, and C.R. King The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand New Biol 2 1990 992
4. K. Hede Gastric cancer: trastuzumab trial results spur search for other targets J Natl Cancer Inst 101 2009 1306
5. R. Berger, D.I. Lin, and M. Nieto Androgen-dependent regulation of HER-2/neu in prostate cancer cells Cancer Res 66 2006 5723
6. N. Craft, Y. Shostak, and M. Carey A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase Nat Med 5 1999 280
7. I.K. Mellinghoff, I. Vivanco, and A. Kwon HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability Cancer Cell 6 2004 517
8. S. Signoretti, R. Montironi, and J. Manola Her-2-neu expression and progression toward androgen independence in human prostate cancer J Natl Cancer Inst 92 2000 1918
9. C.X. Yuan, A.L. Lasut, and R. Wynn Purification of Her-2 extracellular domain and identification of its cleavage site Protein Expr Purif 29 2003 217
10. T. Christianson, J.K. Doherty, and Y.J. Lin NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer Cancer Res 58 1998 5123
11. M.A. Molina, J. Codony-Servat, and J. Albanell Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells Cancer Res 61 2001 4744
12. N. Mantel, and W. Haenszel Statistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 22 1959 719
13. J.S. Krouwer, and K.L. Monti A simple, graphical method to evaluate laboratory assays Eur J Clin Chem Clin Biochem 33 1995 525
14. S. Duval, and R. Tweedie Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis Biometrics 56 2000 455
15. Y. Wen, M.C. Hu, and K. Makino HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway Cancer Res 60 2000 6841
16. Y. Arai, T. Yoshiki, and O. Yoshida c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer Prostate 30 1997 195
17. J. Domingo-Domenech, P.L. Fernandez, and X. Filella Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel Ann Oncol 19 2008 269
18. T. Okegawa, M. Kinjo, and K. Nutahara Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy Int J Urol 13 2006 1197
19. S.F. Shariat, K. Bensalah, and J.A. Karam Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer Clin Cancer Res 13 2007 5377
20. A.P. Fantinato, M. Tobias-Machado, and F. Fonseca Her2/neu expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients Tumori 93 2007 467
21. B.L. Croal, I.D.C. Mitchell, and W.J. Mutch Serum HER-2/neu extracellular domain levels in men presenting with suspected prostate cancer UroOncology 2 2002 99
22. K. Boglou, R.M. Valeri, and N. Dimasis Serum level detection of HER2/neu in patients with prostatic hyerplasia and prostate cancer Cytopathology 19 suppl. 2008 63 abstract 136
23. I. Osman, M. Mikhail, and B. Shuch Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression J Urol 174 2005 2174
24. R.B. Myers, D. Brown, and D.K. Oelschlager Elevated serum levels of p105(erbB-2) in patients with advanced-stage prostatic adenocarcinoma Int J Cancer 69 1996 398
25. A. Ziada, A. Barqawi, and L.M. Glode The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial Prostate 60 2004 332
26. P.N. Lara Jr, K.G. Chee, and J. Longmate Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial Cancer 100 2004 2125
27. J.S. de Bono, J. Bellmunt, and G. Attard Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer J Clin Oncol 25 2007 257
28. D.B. Agus, C.J. Sweeney, and M.J. Morris Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy J Clin Oncol 25 2007 675